231 related articles for article (PubMed ID: 26918827)
1. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
2. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
3. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract][Full Text] [Related]
4. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
5. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck.
Farnebo L; Stjernström A; Fredrikson M; Ansell A; Garvin S; Thunell LK
DNA Repair (Amst); 2015 Jul; 31():64-72. PubMed ID: 26001739
[TBL] [Abstract][Full Text] [Related]
6. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines.
Farnebo L; Jedlinski A; Ansell A; Vainikka L; Thunell LK; Grénman R; Johansson AC; Roberg K
Int J Mol Med; 2009 Oct; 24(4):549-56. PubMed ID: 19724896
[TBL] [Abstract][Full Text] [Related]
10. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients.
Nogueira GAS; Costa EFD; Lopes-Aguiar L; Lima TRP; Visacri MB; Pincinato EC; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Oncotarget; 2018 Jul; 9(51):29538-29547. PubMed ID: 30038702
[TBL] [Abstract][Full Text] [Related]
12. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population.
Paszkowska-Szczur K; Scott RJ; Górski B; Cybulski C; Kurzawski G; Dymerska D; Gupta S; van de Wetering T; Masojć B; Kashyap A; Gapska P; Gromowski T; Kładny J; Lubiński J; Dębniak T
Mol Biol Rep; 2015 Mar; 42(3):755-64. PubMed ID: 25391773
[TBL] [Abstract][Full Text] [Related]
14. Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.
Macedo LT; Costa EFD; Carvalho BF; Lourenço GJ; Calonga L; Castilho AM; Chone CT; Lima CSP
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980643
[TBL] [Abstract][Full Text] [Related]
15. Genetic Polymorphisms of XPC, XPD, XPG Genes and their Association with Radiotherapy Induced Toxicity among Head and Neck Cancer Patients: A Hospital Based Study from Maharashtra.
Gudur AK; Kale SR; Gudur RA; Bhosale SJ; Datkhile KD
Asian Pac J Cancer Prev; 2024 Jan; 25(1):191-199. PubMed ID: 38285784
[TBL] [Abstract][Full Text] [Related]
16. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
18. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
19. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck.
Sturgis EM; Dahlstrom KR; Spitz MR; Wei Q
Arch Otolaryngol Head Neck Surg; 2002 Sep; 128(9):1084-8. PubMed ID: 12220217
[TBL] [Abstract][Full Text] [Related]
20. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
